A new bispecific antibody drug has been approved for extensive-stage small cell lung cancer, marking an advance in the treatment of a disease with high relapse rates and very few therapy options. The drug, Imdelltra (tarlatamab), was given an accelerated approval by the US Food and Drug Administration on 16 May following a Phase 2 trial in patients with small cell lung cancer who had failed two or more prior lines of treatment. The developer is Amgen Inc.
